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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A354nociceptors. MSCs were recorded in the cell-attached conﬁguration and
were stimulated with a high-speed pressure clamp (HSPC) device.
Results: Our behavioral observations indicate that MIA-injected mice
become hypersensitive to knee ﬂexion and extension. Electro-
physiology recordings from acutely dissociated knee nociceptors indi-
cate that there are no changes in the resting membrane potential.
However, our data indicates that the activation threshold of MSCs in the
nociceptors of OA mice is signiﬁcantly lower than that of nociceptors
from naïve mice. Moreover, there is a greater elicited mechanosensitive
current in OA nociceptors.
Conclusions: Our data suggest that the lowered threshold of MSCs may
contribute to the mechanical hypersensitivity observed in behavioral
tests. MSCs in nociceptors may be a novel therapeutic target in the
treatment of OA pain.
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LYSOPHOSPHATIDIC ACID CONTRIBUTES TO THE DEVELOPMENT OF
NEUROPATHIC PAIN IN RODENT KNEE JOINTS
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Purpose: Since a subset of osteoarthritis (OA) patients are unresponsive
to classic analgesics, it has been postulated that OA pain may have a
neuropathic component. The lipid mediator lysophosphatidic acid (LPA)
is found in arthritic joints and has been shown to cause peripheral
neuropathy and neuropathic pain-like symptoms in skin. The present
study investigated the effect of LPA on joint nerve morphology and pain
generation in rats.
Methods: Male Lewis rats (300-350g) had 50mg of LPA injected into
their right knee joint and allowed to recover for 3 weeks. Animals
were then euthanized and the ipsilateral saphenous nerve was
removed and ﬁxed in 4% paraformaldehyde. The nerve was then
prepared and sectioned for electron microscopic analysis of axon
myelination using G ratio calculations (internal neuronal area divided
by total area). Dorsal root ganglia (DRG L3-L5) were also removed,
ﬁxed and embedded in optimal cutting temperature compound.
Sections of DRG were stained for the nerve degeneration marker ATF-
3. In separate studies, 50mg, 100mg and 200mg of LPA were injected
into the right knee and pain assessed 1, 4, 9, 15 and 51 days post
intra-articular injection by differential weight bearing using an inca-
pacitance tester.
Results: Intra-articular injection of LPA caused a signiﬁcant increase in
G-ratio (P<0.05) indicative of demyelination. Similarly, LPA treatment
caused a heightened expression of ATF-3 in ipsilateral nerve cell bodies.
In animals assessed for pain, all 3 doses of LPA elicited a dose-
dependent pain response. The pain persisted after a single LPA injection
out to 51 days post injection.
Conclusions: These data indicate that intra-articular injection of LPA
caused a peripheral neuropathy with associated pain behaviour. Phar-
macological blockade of LPA receptors or a reduction in its formation
may be an efﬁcacious means of controlling neuropathic pain in the
subset of OA patients that do not respond to classic analgesics.
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CORTICAL SINGULARITY OF KNEE OSTEOARTHRITIS PATIENTS AND
THEIR RESPONSE TO DULOXETINE OR PLACEBO TREATMENT
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A. Apkarian. Northwestern Univ., Chicago, IL, USA
Purpose: Structural and functional brain changes have been shown to
be associated with the development and regression of chronic pain. This
study was undertaken to determine the brain structural characteristics
that correlate with response to duloxetine (DLX) and placebo (P)
treatment in patients with knee OA.
Methods: 40 participants were entered into a randomized, controlled
trial of DLX 60 mg qd vs matching P. All participants met ACR radio-
graphic and clinical criteria for knee OA, had pain  4 on 11 point NRS
scale, met all inclusion and exclusion criteria, and were treated for 4
months with pain measurements at weeks 0, 2, 3, 6 and 16. Anatomic
MRI scans were done at baseline and at end of treatment. The total gray
matter volume of the brainwas obtained using the SIENAX tool from FSL
and cortical gray matter density (GMD) changes were evaluated using a
voxel based morphometry approach (FSL-VBM). To evaluate structuralbrain properties, longitudinal contrast was made by using a two-way
repeated measure ANOVA design.
Results: Although there was no overall difference in the mean pain
response between treatment groups ( p¼0.87), both the DLX and P
groups included participants who had a signiﬁcant pain response (
20% pain decrease from baseline, hence classiﬁed as “responders or þ”)
as well as those with lesser or no response (“non-responders or -”).
When the brain morphology of each of these 4 groups (DLX þ and DLX
-; P þ and P -) was assessed from their baseline visits, prior to any
treatment, signiﬁcant regional GMD differences were observed in
extensive regions across the brain (Fig. 1). Whole-brain voxel-wise VBM
contrast (before - after treatment) revealed that DLX-treated patients
underwent modiﬁcation in GMD in the left precentral gyrus, left middle
frontal gyrus and bilateral ACC (ﬁgure 2A). Interestingly, when patients
positively responded to their treatment, independent of the compound
received, differences in GMD were observed only in the left precentral
gyrus (ﬁgure 2B). In addition, regions in the left middle frontopolar
(ﬁgure 2C) and inferior temporal gyri showed GMD changes when DLX
induced pain relief. We thus show that some cortical regions presenting
GMD reorganization were shared among all 4 groups studied, sug-
gesting that a proportion of gray matter structural modiﬁcation may be
naturally occurring in time while other regional changes are directly
related to treatment received.
Conclusions: Treatment in participants with OA pain is affecting cort-
ical reorganization in a way that is dependent on the type of treatment,
the treatment response and the interaction of both. Understanding how
placebo and pharmacological treatment affect structural brain proper-
ties is important to allow more personalized approaches to therapy in
OA pain.
Figure 1. Differences in Gray matter density (GMD) is observe within
the 40 OA subjects before the beginning of the treatment. This f map
was obtained after performing a cross-sectional one-way ANOVA on the
40 OA subjects at the ﬁrst scanning session. This map revealed the areas
where GMD differences are identiﬁed when comparing the 4 sub-groups
of OA subjects present in our study.
Figure 2. Treatment received, pain decrease and their interaction induce
unique gray matter reorganization. Two-way repeated measure ANOVA
revealed that A) DLX and P induce opposite GM modiﬁcation in bilateral
ACC. B) Response to the treatment is affecting cortical changes in a region
in the left precentral gyrus (primary motor cortex) and C) Prefrontal
cortex undergoes high GM reorganization for DLX-patients that show pain
decrease. DLX ¼ Duloxetine. P ¼ Placebo, þ ¼ responders, - ¼ non-
responders.
